“Growing Adoption of Drug-Eluting Balloons”
A key trend in the angioplasty balloons market is the growing adoption of drug-eluting balloons (DEBs). This trend is driven by the need to improve treatment outcomes and reduce restenosis rates in patients undergoing angioplasty procedures. DEBs are coated with medication that helps prevent the re-narrowing of arteries by releasing the drug directly at the site of the blockage. This localized drug delivery approach provides a more targeted and effective treatment compared to traditional bare-metal balloons. The trend toward DEBs is gaining momentum due to their ability to reduce the need for additional stent implantation and minimize the risk of complications such as vessel re-blockage. As a result, DEBs are increasingly being used in both coronary and peripheral vascular procedures. The growing preference for DEBs is largely driven by their improved efficacy in preventing restenosis, which is a major concern in angioplasty, making them a popular choice among healthcare professionals and patients alike.
